Oussema Denguir ...
  • Pierre Corby

Zealand Pharma : Substantial newsflow for the next twelve months

>Q1 2019 results - Zealand Pharma yesterday afternoon reported its financial results for Q1 2019. No sales recorded over the period (after the sale of the rights for Soliqua and Lyxumia to Royalty Pharma last September), the operating loss widened to DKK 136m (vs -DKK 88m in Q1 2018) underscoring the decline in revenues and the rise in opex (R&D +36% to DKK 121m; +80% SG&A to DKK 14.5m) which reflects the progress of the development of the various molecules in its pip...
Zealand Pharma A/S

Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.


​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Oussema Denguir

Pierre Corby

Other Reports on these Companies
Other Reports from ODDO BHF
Other Reports from these Analysts
Antoine Augier de Lajallet ...
  • Fatma Agnès Hamdani
  • Jean-François Granjon
  • Jeremy Garnier
  • Pierre Corby
  • Sebastien Malafosse
  • Vincent Baron

ResearchPool Subscriptions

Get the most out of your insights

Get in touch